Abiopharma

🔍 Dimension Capital II, L.P. (Director)

Company: Odyssey Therapeutics, Inc. (ODTX)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 1,709,543 shares of Common Stock (Direct)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | shares_owned_after: 2,222,405.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,111,111 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-08 | Code: P | equity_swap_involved: 0 | shares_owned_after: 3,333,516.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,709,543 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-08 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F4, F2

Footnotes:

• F1: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F2: Held directly by Dimension Capital II, L.P. ("Dimension Capital II"). Dimension Management, L.P. ("Dimension Management") is the investment advisor to Dimension Capital II. Dimension Management GP, L.P. is the general partner of Dimension Management, and Dimension Management GP, LLC ("Dimension Management GP") is the general partner of Dimension Management GP, L.P. Dimension Capital II GP, LLC ("Dimension Capital II GP") is the general partner to the general partner of Dimension Capital II. Adam Goulburn, Zavain Dar, and Nan Li are members of each of Dimension Management GP and Dimension Capital II GP. Mr. Li serves on the Issuer's board of directors.
• F3: Each of Dimension Management, Dimension Management GP, Dimension Capital II GP, Mr. Goulburn, Mr. Dar, and Mr. Li disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
• F4: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.